Powerful New Strategies for Drug Discovery
Analysis of Phase II drug failures (Arrowsmith, 2011; Arrowsmith and Miller, 2013) identifies lack of efficacy as the most frequent cause of attrition, suggesting that existing in vitro and in vivo disease models are not well-translated to human disease. Efficacy obstacles are especially problematic for clinical targets, such as the central nervous system (CNS), with notoriously unpredictive animal models. Together, CDI’s iCell® and MyCell® Products enable powerful new strategies for overcoming these hurdles:
- iCell Products: Differentiated human iPS cells drive disease modeling and drug screening initiatives in a variety of clinical areas including cardiac hypertrophy, Alzheimer’s disease, and diabetes
- MyCell Products and MyCell Disease & Diversity Products: Biologically relevant human cells from cohorts of donors with specific disease-associated genotypes and phenotypes fuel early-stage drug discovery efforts
Contact us to learn how CDI’s iPS cell platform gives scientists a more in-depth biological understanding of drug targets and improved target validation approaches.